Abstract. Epithelial cell transforming sequence 2 (ECT2) is a guanine nucleotide exchange factor encoded by the ECT2 gene, which is located on the 3q26.31 chromosomal region and is directly associated with the occurrence of cancers. The aim of the present study was to examine the expression and prognostic importance of ECT2 in various breast cancer subtypes using the online tools, Gene Expression Profiling Interactive Analysis, Kaplan-Meier-plotter and bc-GenExMiner. ECT2 mRNA expression was significantly different in oestrogen receptor ER(+) breast cancer; overexpression of ECT2 was associated with poor prognosis in ER + breast cancer. The mRNA expression levels of ECT2 were increased in basal-like breast cancer and triple negative breast cancer, but were not significant for prognostic prediction. We identified ECT2-correlated genes and their corresponding Gene Ontology (GO) enrichment terms. The results revealed that GO: 0005524 (protein binding) had the greatest number of correlated genes and also contained ECT2. This suggested that overexpression of ECT2 may be a significant prognostic factor for poor outcome in ER + breast cancer; however, the precise role of ECT2 in breast cancer requires further investigation.
Introduction
Breast cancer is the second most common type of cancer worldwide, with the highest incidence and leading cause of mortality in females (1) . According to data from Globocan, ~1.67 million novel cases of breast cancer were diagnosed in 2012 (2) . The rates of incidence vary between less developed and developed countries, with rates ranging from 27 cases per 100,000 in Central Africa and Eastern Asia compared with 96 cases per 100,000 in Western Europe (2) . In China, the largest developing and highly populated country worldwide, and has a low incidence of breast cancer; however, the burden of breast cancer in China is increasing annually (3) . In 2008, 169,452 novel cases of breast cancer and 44,908 breast cancer-associated mortalities in China were reported, accounting for 12.2% of cases and 9.6% of associated mortalities globally (4) . At present, the 5-year survival rate for primary breast cancer is relatively high, at 92% (5); however, the survival rate of patients with metastatic breast cancer remains <25% (2, 5) . Developments concerning the pathogenesis of breast cancer have been made, yet few drugs for the treatment of breast cancer exhibit satisfactory outcomes. Therefore, investigating the occurrence and development of breast cancer is a primary research objective.
Epithelial cell transforming sequence 2 (ECT2) is a guanine nucleotide exchange factor encoded by the ECT2 gene in humans and is directly associated with the occurrence of cancers (6) . ECT2 is primarily upregulated in certain cancers and is considered a major oncogene involved in the onset or progression of cancer (7, 8) . In ovarian cancers, ECT2 mRNA is frequently amplified, and the protein is highly expressed in the nucleus but not in the cytoplasm in advanced disease; ECT2 acts as a Rho guanine nucleotide exchange factor specifically within the nucleus to drive ovarian cancer cell transformation (9) . In breast cancer cells, ECT2 serves a significant role in the progression of breast cancer (10); however, the effects of ECT2 on the prognosis of different molecular types of breast cancer remains unclear. In the present study, Breast Cancer Gene-Expression Miner v4.1 (11) , was employed to analyse the expression of ECT2 in various types of breast cancer. The aim of our study was to investigate whether ECT2 expression could predict the prognosis of different types of breast cancer.
Materials and methods
Gene expression levels of ECT2. We obtained the RNA sequence and expression profile of ECT2 in normal and tumour tissues from Gene Expression Profiling Interactive Analysis (GEPIA; http://gepia.cancer-pku.cn/index.html, using a standard system to analyse 9,736 tumour and 8,587 normal samples from the Cancer Genome Atlas (TCGA; https://cancergenome.nih.gov/) and Genotype-Tissue Expression projects (12 
Results

ECT2 expression in different types of breast cancer tissue and normal breast tissues.
Using GEPIA expression analysis, it was revealed that the expression of ECT2 was significantly higher in breast cancer tissues compared with normal breast tissues (P<0.0001; Fig. 1A ). We used bc-GenExMiner to demonstrate that ECT2 expression significantly varied in PAM50 subtypes (P<0.0001; Fig. 1B ), and basal-like breast cancer exhibited higher ECT2 expression than all other subtypes.
OS and PFS of patients with breast cancer exhibiting high and low expression levels of ECT2.
Survival analysis from the Kaplan-Meier-plotter was employed to confirm whether high ECT2 expression was associated with significantly worse OS (P=3.7x10 succumbed by the last time point in the low ECT2 expression group; however, high ECT2 expression was associated with significantly worse PFS.
ECT2 expression and OS in patients with ER
+ and ER -breast cancer. There were 12 significant results (P<0.05) among the 18 total findings from the Univariate Cox analysis from bc-GenExMiner v4.1 data (Table I ). ECT2 mRNA expression was significantly different between patients with ER + and ER -breast cancer (Fig. 3A) ; ECT2 expression was upregulated in ER -breast cancer than in ER + breast cancer. On the contrary, the present study reported that higher expression levels of ECT2 (Fig. 3B) , while the expression of ECT2 in patients with ER -breast cancer was not significantly associated with survival (Fig. 3C) .
ECT2 expression and OS in patients with basal-like breast
cancer and/or TNBC. There were no significant differences (P>0.05) among the three total results from univariate Cox analysis of ECT2 for the survival of patients with basal-like and/or TNBC from bc-GenExMiner v4.1 data (Table II) . Significant differences in the expression of ECT2 mRNA between patients with basal-like breast cancer and/or TNBC were observed. The expression levels of ECT2 mRNA in patients with basal-like breast cancer and/or TNBC were upregulated than in patients without these subtypes (P<0.05; Fig. 4A ). In addition, the expression of ECT2 was not associated with OS in basal-like breast cancer and/or TNBC with concomitant AE via KM analysis (P>0.05; Fig. 4B ).
Genes correlated with ECT2. The top 10 closest positive/negative correlations with ECT2 were identified via extensive gene correlation analysis of breast cancer (Table III) . Then, GO enrichment analysis was performed for the genes correlated with ECT2 via bc-GenExMiner (Table IV) . Among them, GO:0005524 (protein binding) had the greatest number of associated genes and also contained ECT2 itself.
Discussion
The ECT2 gene was initially identified as a proto-oncogene located in the 3q26.31 chromosomal region that can transform NIH/3T3 fibroblasts into cancer cells (14) . As a guanine nucleotide exchange factor of the Rho guanosine triphosphate (GTP)ase family, ECT2 regulates cell division and the cell cycle (15, 16) , which affects various biological functions, including the proliferation, invasion and migration of tumour cells, associated with numerous signalling pathways (17) (18) (19) . ECT2 catalyses the dissociation of bound guanosine diphosphate (GDP) and promotes the replacement of GDP with GTP, thereby activating Ras GTP enzymes in cell signalling pathways (20, 21) . A study indicated that the formation of lung cancer depends on rRNA synthesis regulated by ECT2 (22) . Numerous studies have reported that ECT2 expression correlated with the prognosis of patients with prostate cancer and gastrointestinal tumours, including gastric cancer, colorectal cancer and oesophageal cancer (15, 21, 23, 24) . The present study demonstrated that the expression of ECT2 was significantly higher in breast cancer tissues than in normal breast tissues using data from GEPIA. Therefore, ECT2 may serve an important role in the occurrence and development of breast cancer. Furthermore, the expression of ECT2 in PAM50 subtypes was significantly different as determined (24) . In the present study, it was observed that high ECT2 expression was associated with significantly lower OS and PFS in patients with breast cancer using KM-plotter. In addition, we determined that ECT2 expression was lower in ER + breast cancer; however, increased expression of ECT2 was associated with the poor prognosis of ER + breast cancer, as demonstrated by ECT2 univariate Cox and KM curve analyses of bc-GenExMiner v4.1 data. Although, the expression of ECT2 in ER -breast cancer was higher than in ER + breast cancer, our results indicated that the high expression of ECT2 in ER + breast cancer may be associated with poor prognosis. These results suggest the potential of ECT2 as a biomarker and a therapeutic target for ER + breast cancer. Recently, TNBC and ECT2 were reported to be independent prognostic factors for patients with breast cancer (25) . On the contrary, the results of the present study indicated that ECT2 expression is higher in basal-like breast cancer and TNBC; however, ECT2 was not an independent prognostic factor for both of these subtypes. In addition, we conducted GO enrichment for genes correlated with ECT2 via GO analysis of bc-GenExMiner v4.1 data. The results revealed that GO: 0005524 (protein binding) had the greatest number of genes correlated with and contained ECT2, which may provide insight into the mechanism of ECT2 in the progression of breast cancer; however, further investigation is required. The mechanism of ECT2 action in breast cancer must be confirmed by prospective experiments in vitro and in vivo.
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In conclusion, ECT2 may represent a novel therapeutic target for the treatment of cancer based on its role in the occurrence and development of breast cancer, as well as its independent prognostic significance.
